StockNews.com Begins Coverage on Oncternal Therapeutics (NASDAQ:ONCT)

StockNews.com initiated coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a research note published on Thursday morning. The firm issued a hold rating on the stock.

Several other equities research analysts also recently issued reports on the company. Northland Capmk downgraded Oncternal Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, September 12th. Northland Securities restated a “market perform” rating and set a $2.00 price target on shares of Oncternal Therapeutics in a report on Thursday, September 12th. HC Wainwright dropped their price objective on shares of Oncternal Therapeutics from $19.00 to $18.00 and set a “buy” rating on the stock in a research note on Monday, August 12th. Finally, Brookline Capital Management reissued a “hold” rating on shares of Oncternal Therapeutics in a research note on Thursday, September 12th. Four research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $10.00.

Oncternal Therapeutics Price Performance

ONCT opened at $0.53 on Thursday. The firm has a market capitalization of $1.56 million, a P/E ratio of -0.05 and a beta of 1.18. The stock has a fifty day moving average of $1.20 and a 200-day moving average of $4.34. Oncternal Therapeutics has a 12-month low of $0.53 and a 12-month high of $13.14.

Institutional Investors Weigh In On Oncternal Therapeutics

A hedge fund recently bought a new stake in Oncternal Therapeutics stock. Pasadena Private Wealth LLC bought a new stake in Oncternal Therapeutics, Inc. (NASDAQ:ONCT) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 25,000 shares of the company’s stock, valued at approximately $190,000. Pasadena Private Wealth LLC owned about 0.84% of Oncternal Therapeutics as of its most recent SEC filing. Institutional investors own 16.05% of the company’s stock.

About Oncternal Therapeutics

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.